Table 4.
Effect of study group on pathological attributes of interval cancers and second round screen-detected cancers
| Size (mm) | Grade | Node status | Stage | Laterality | Tumour risk group | |||||||||||||
| 20+ | < 20 | Odds ratioa | 3 | 1+2 | Odds ratiob | +ve | -ve | Odds ratioc | 2+ | 1 | Odds ratiod | Left | Right | Odds ratioe | 3 | 1 + 2 | Odds ratiof | |
| Interval cancer | ||||||||||||||||||
| Nonassessed | 160 | 124 | 1.00 | 72 | 148 | 1.00 | 101 | 133 | 1.00 | 179 | 131 | 1.00 | 139 | 162 | 1.00 | 75 | 216 | 1.00 |
| Assessed normal | 26 | 14 | 1.44 (0.72–2.87) | 5 | 22 | 0.47 (0.17–1.28) | 13 | 18 | 0.95 (0.45–2.03) | 25 | 15 | 1.22 (0.62–2.40) | 22 | 17 | 1.51 (0.77–2.95) | 4 | 34 | 0.34 (0.12–0.99) |
| Assessed benign | 1 | 1 | 0.78 (0.05–12.51) | 1 | 0 | - | 1 | 2 | 0.66 (0.06–7.36) | 1 | 2 | 0.37 (0.03–4.08) | 2 | 2 | 1.17 (0.16–8.38) | 2 | 2 | 2.88 (0.40–20.81) |
| All assessed | 27 | 15 | 1.40 (0.71–2.74) | 6 | 22 | 0.56 (0.22–1.44) | 14 | 20 | 0.92 (0.44–1.91) | 26 | 17 | 1.12 (0.58–2.15) | 24 | 19 | 1.47 (0.77–2.80) | 6 | 36 | 0.48 (0.19–1.18) |
| Second screen cancer | ||||||||||||||||||
| Nonassessed | 78 | 275 | 1.00 | 57 | 256 | 1.00 | 72 | 206 | 1.00 | 104 | 253 | 1.00 | 180 | 172 | 1.00 | 54 | 294 | 1.00 |
| Assessed normal | 11 | 24 | 1.62 (0.76–3.44) | 5 | 23 | 0.98 (0.36–2.68) | 10 | 19 | 1.51 (0.67–3.39) | 13 | 22 | 1.44 (0.70–2.96) | 16 | 16 | 0.96 (0.46–1.97) | 4 | 30 | 0.73 (0.25–2.14) |
| Assessed benign | 0 | 1 | - | 0 | 1 | - | 0 | 1 | - | 0 | 1 | - | 0 | 1 | - | 0 | 1 | - |
| All assessed | 11 | 25 | 1.55 (0.73–3.29) | 5 | 24 | 0.94 (0.34–2.56) | 10 | 20 | 1.43 (0.64–3.20) | 13 | 23 | 1.37 (0.67–2.82) | 16 | 17 | 0.90 (0.44–1.84) | 4 | 31 | 0.70 (0.24–2.07) |
| All cancers | ||||||||||||||||||
| Nonassessed | 238 | 399 | 1.00 | 129 | 404 | 1.00 | 173 | 339 | 1.00 | 283 | 384 | 1.00 | 319 | 334 | 1.00 | 129 | 510 | 1.00 |
| Assessed normal | 37 | 38 | 1.63 (1.01–2.64) | 10 | 45 | 0.70 (0.34–1.42) | 23 | 37 | 1.22 (0.70–2.11) | 38 | 37 | 1.39 (0.86–2.25) | 38 | 33 | 1.21 (0.74–1.97) | 8 | 64 | 0.49 (0.23–1.06) |
| Assessed benign | 1 | 2 | 0.84 (0.08–9.29) | 1 | 2 | 1.57 (0.14–17.41) | 1 | 3 | 0.65 (0.07–6.33) | 1 | 3 | 0.45 (0.05–4.37) | 2 | 3 | 0.70 (0.12–4.21) | 2 | 3 | 2.64 (0.44–15.94) |
| All assessed | 38 | 40 | 1.59 (0.99–2.55) | 11 | 47 | 0.73 (0.37–1.46) | 24 | 40 | 1.18 (0.69–2.01) | 39 | 40 | 1.32 (0.83–2.11) | 40 | 36 | 1.16 (0.72–1.87) | 10 | 67 | 0.59 (0.30–1.18) |
a Odds ratio of cancer measuring 20 mm and above versus < 20 mm. b Odds ratio of cancer of grade 3 versus grades 1 or 2. c Odds ratio of node positive cancer versus node negative. d Odds ratio of cancer of stage 2 or above versus stage 1. e Odds ratio of cancer in the left breast versus in the right breast. f Odds ratio of cancer of risk group 3 versus risk groups 1 or 2 [9].